Elite Pharmaceuticals ELTP
OTC ELTP
$0.37 +0.05 (+15.63%)
As of: Nov 16, 2026 · 3:54 PM EST

Elite Pharmaceuticals (ELTP) EBITDA Margin (2009 - 2026)

Updated

Elite Pharmaceuticals' EBITDA Margin was 25.72% in fiscal Q2 2027 (quarter ended Sep 30, 2026), up 2.02 percentage points from 23.70% a year earlier and up 1.31 percentage points from the prior quarter.

Analysis

Elite Pharmaceuticals (ELTP) EBITDA Margin (2009 - 2026) Analysis & Trends

On a trailing twelve-month basis, Elite Pharmaceuticals' EBITDA Margin was 26.36% through Sep 30, 2026, down 9.28 percentage points year-over-year; for FY2026 (ended Mar 31, 2026), it was 34.03%, up 8.70 percentage points from FY2025.

  • EBITDA Margin has now increased for three consecutive fiscal years, with a five-year change of +20.56 percentage points (FY2021 to FY2026).
  • In earlier fiscal years, EBITDA Margin was 25.33% in FY2025 (+3.86 pp), 21.47% in FY2024 (+6.96 pp), 14.50% in FY2023 (-4.96 pp) and 19.47% in FY2022 (+6.00 pp).
  • Quarterly EBITDA Margin has moved between -0.50% (fiscal Q4 2023) and 54.95% (fiscal Q1 2026) over five years.
  • Compared with a year earlier, EBITDA Margin was higher in five of the last eight quarters, with an average year-over-year change of +1.87 percentage points.
  • The best year-over-year quarter for EBITDA Margin over five years was fiscal Q1 2026 (a gain of 32.13 percentage points); the worst was fiscal Q1 2027 (a drop of 30.54 percentage points).
  • Per Business Quant data, ELTP's EBITDA Margin in the three fiscal quarters before Q2 2027 was 24.41% (Q1 2027), 25.91% (Q4 2026) and 29.76% (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 32.68%
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 46.88%
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 40.60%
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 39.77%
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 46.62%
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 50.63%
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 42.49%
10 Elite Pharmaceuticals 401.23 Mn 274.64 Mn 15.99 Mn 25.72%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 25.72%
Jun 30, 2026 24.41%
Mar 31, 2026 25.91%
Dec 31, 2025 29.76%
Sep 30, 2025 23.70%
Jun 30, 2025 54.95%
Mar 31, 2025 36.14%
Dec 31, 2024 10.65%
Sep 30, 2024 20.30%
Jun 30, 2024 22.81%
Mar 31, 2024 22.82%
Dec 31, 2023 24.90%
Sep 30, 2023 15.91%
Jun 30, 2023 21.50%
Mar 31, 2023 -0.50%
Dec 31, 2022 24.61%
Sep 30, 2022 16.31%
Jun 30, 2022 17.19%
Mar 31, 2022 15.02%
Dec 31, 2021 23.71%
API Access

Elite Pharmaceuticals EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ELTP&period=max&api_key=YOUR_API_KEY